Methodology and application of adaptive and sequential approaches in contemporary clinical trials
From MaRDI portal
Publication:1929694
DOI10.1155/2012/527351zbMath1282.62230WikidataQ58910970 ScholiaQ58910970MaRDI QIDQ1929694
Jeanne Kowalski, Ye Cui, Zhengjia Chen, Yichuan Zhao
Publication date: 9 January 2013
Published in: Journal of Probability and Statistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1155/2012/527351
62P10: Applications of statistics to biology and medical sciences; meta analysis
62F35: Robustness and adaptive procedures (parametric inference)
62L05: Sequential statistical design
Uses Software
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- A review of phase 2-3 clinical trial designs
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Seamlessly Expanding a Randomized Phase II Trial to Phase III
- Design and Analysis of Phase I Clinical Trials
- Designs for Group Sequential Phase II Clinical Trials
- One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- An improved method for deriving optimal one-sided group sequential tests
- Designed Extension of Studies Based on Conditional Power
- Optimal asymmetric one-sided group sequential tests
- Modification of Sample Size in Group Sequential Clinical Trials
- A Sample-Size-Optimal Bayesian Procedure for Sequential Pharmaceutical Trials
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
